In-stent restenosis of the renal artery in a single kidney patient: The role of acei in the therapeutic choice

Angiology

Volumn 60, Issue 4, 2009, Pages 496-503

  Cianci, Rosario ^a   Gigante, Antonietta ^a   Polidori, Lelio ^a   Di Donato, Domenico ^a   Martina, Paola ^a   Barbano, Biagio ^a   Renzulli, Roberta ^a   Zaccaria, Alvaro ^b   Fuiano, Giorgio ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Hypertension; Renal artery stenosis; Renal ischemia; Secondary renal disease

Indexed keywords

AMILORIDE; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANGIOTENSIN II; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FIBRINOGEN; HOMOCYSTEINE; LIPOPROTEIN A; METOPROLOL; NIFEDIPINE; RAMIPRIL; ANTIHYPERTENSIVE AGENT;

AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CASE REPORT; CLINICAL FEATURE; COLOR ULTRASOUND FLOWMETRY; DISEASE COURSE; DRUG CHOICE; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IN-STENT RESTENOSIS; KIDNEY ARTERY STENOSIS; KIDNEY FAILURE; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RENOVASCULAR DISEASE; SOLITARY KIDNEY; STENT; SURVIVAL RATE; ACUTE KIDNEY FAILURE; BLOOD PRESSURE; DRUG EFFECT; HOSPITALIZATION; INSTRUMENTATION; KIDNEY DISEASE; PATIENT SELECTION; RECURRENT DISEASE; RENOVASCULAR HYPERTENSION; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE PROGRESSION; HUMANS; HYPERTENSION, RENOVASCULAR; KIDNEY DISEASES; KIDNEY FAILURE, ACUTE; MALE; PATIENT SELECTION; RECURRENCE; RENAL ARTERY OBSTRUCTION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STENTS; TREATMENT OUTCOME;

EID: 70349560851     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319708322172     Document Type: Article

References (55)

1. Poggio ED, Nef PC, Wang X., et al. Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis. 2005 ; 46: 242-252. (Pubitemid 41040352)
2. Olin JW, Melia M., Young JR, Graor RA, Risius B. Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med. 1990 ; 88: 46N - 51N.
3. Preston RA, Epstein M. Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. J Hypertens. 1997 ; 15 (12 Pt 1). 1365-1377.
4. Safian RD, Textor SC, Renal-artery stenosis. N Engl J Med. 2001 ; 344: 431-442.
5. Zierler RE, Bergelin RO, Davidson RC, Cantwell-Gab K., Polissar NL, Strandness De Jr. A prospective study of disease progression in patients with atherosclerotic renal artery stenosis. Am J Hypertens. 1996 ; 9: 1055-1061.
6. Olin JW, Begelman SM Renal artery disease. In: Topol E, ed. Textbook of Cardiovascular Medicine. 2 nd ed. Philadelphia, PA: Lippincott Raven ; 2002: 2139-2159.
7. Gray BH, Olin JW, Childs MB, Sullivan TM, Bacharach JM Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure. Vasc Med. 2003 ; 17: 275-279.
8. Olin JW Renal artery disease: diagnosis and management. Mt Sinai J Med. 2004 ; 71: 73-85.
9. Rimmer J., Gennari FJ Atherosclerotic renovascular disease and progressive renal failure. Ann Intern Med. 1993 ; 118: 712-719.
10. Textor SC, Tarazi RC, Novick AC, Bravo El, Fouad FM Regulation of renal hemodynamics and glomerular filtration rate in patients with renovascular hypertension during converting enzyme inhibition with captopril. Am J Med. 1984 ; 76 (5B). 29-37.
11. Silas JH, Klenka Z., Solomon SA, Bone JM Captopril induced reversible renal failure: a marker for renal artery stenosis affecting a solitary kidney. Br Med J (Clin Res Ed). 1983 ; 286: 1702-1703.
12. Jacobson HR Ischemic renal disease: an overlooked clinical entity ? Kidney Int. 1988 ; 34: 729-743.
13. MacDowall P., Kalra PA, Oĝ™Donoghue DJ, Waldek S., Mamtora H., Brown K. Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. Lancet. 1998 ; 352: 13-16.
14. Murphy TP, Soares G., Kim M. Increase in utilization of percutaneous renal artery inteventions by Medicare beneficiaries 1996-2000. AJR Am J Roentgenol. 2004 ; 183: 561-568.
15. Coen G., Manni M., Giannoni MF, et al. Ischemic nephropathy in an elderly nephrologic and hypertensive population. Am J Nephrol. 1998 ; 18: 221-227.
16. Schreiber MJ, Pohl MA, Novick AC The natural history of atherosclerotic and fibrous renal artery disease. Urol Clin North Am. 1984 ; 11: 383-392.
17. Zierler RE, Bergelin RO, Isaacson JA, Strandness De Jr. Natural history of renal artery stenosis: a prospective study with duplex ultrasound. J Vasc Surg. 1994 ; 19: 250-257.
18. Novick AC, Textor SC, Bodie B., Khauli RB Revascularization to preserve renal function in patients with atherosclerotic renovascular disease. Urol Clin North Am. 1984 ; 11: 477-490.
19. Caps MT, Zierler RE, Polissar NL, et al. Risk of atrophy in kidneys with atherosclerotic renal artery stenosis. Kidney Int. 1998 ; 53: 735-742.
20. Higashi Y., Sasaki S., Nakagawa K., Matsuura H., Oshima T., Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med. 2002 ; 346: 1954-1962.
21. Textor SC Ischemic nephropathy: where are we now ? J Am Soc Nephrol. 2004 ; 15: 1974-1982.
22. Zoja C., Abbate M., Remuzzi G. Progression of chronic kidney disease: insights from animal models. Curr Opin Nephrol Hypertens. 2006 ; 15: 250-257.
23. Scolari F., Tardanico R., Zani R., et al. Cholesterol crystal embolism: a recognizable cause of renal disease. Am J Kidney Dis. 2000 ; 36: 1089-1109.
24. Textor SC, Novick A., Tarazi RC, Klimas V., Vidt DG, Pohl M. Critical perfusion pressure for renal function in patients with bilateral atherosclerotic renal vascular disease. Ann Intern Med. 1985 ; 102: 308-314.
25. Nicoletti A., Heudes D., Mandet C., Hinglais N., Bariety J., Michel JB Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats. Cardiovasc Res. 1996 ; 32: 1096-1107.
26. Johnstone MT, Perez AS, Nasser I., et al. Angiotensin receptor blockade with candesartan attenuates atherosclerosis, plaque disruption, and macrophage accumulation within the plaque in a rabbit model. Circulation. 2004 ; 110: 2060-2065.
27. Chade AR, Rodriguez-Porcel M., Herrmann J., et al. Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol. 2004 ; 15: 958-966. (Pubitemid 38375315)
28. Brasier AR, Recinos A., Eledrisi MS Vascular inflammation and the rennin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002 ; 22: 1257-1266.
29. Diet F., Pratt RE, Berry GJ, Momose N., Gibbons GH, Dzau VJ Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996 ; 94: 2756-2767.
30. Hoshida S., Kato J., Nishino M., et al. Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. Circulation. 2001 ; 103: 630-633.
31. Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation. 1998 ; 98: 800-807.
32. Schieffer B., Schieffer E., Hilfiker-Kleiner D., et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000 ; 101: 1372-1378.
33. Yang BC, Phillips MI, Mohuczy D., et al. Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998 ; 18: 1433-1439.
34. El Bekay R., Alvarez M., Monteseir-n J., et al. Oxidative stress is a critical mediator of the angiotensin II signal in humanneutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB. Blood. 2003 ; 102: 662-671.
35. Pastore L., Tessitore A., Martinotti S., et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation. 1999 ; 100: 1646-1652.
36. Gibbons GH, Pratt RE, Dzau VJ Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest. 1992 ; 90: 456-461.
37. Naftilan AJ, Pratt RE, Dzau VJ Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest. 1989 ; 83: 1419-1424.
38. Williams B., Baker AQ, Gallacher B., Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension. 1995 ; 25: 913-917.
39. Kagami S., Border WA, Miller DE, Noble NA Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994 ; 93: 2431-2437.
40. Kim S., Iwao H. Molecular and cellular mechanisms of angiotensin II mediated cardiovascular and renal diseases. Pharmacol Rev. 2000 ; 52: 11-34.
41. Kim S., Ohta K., Hamaguchi A., et al. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther. 1995 ; 273: 509-515.
42. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin- angiotensin system and fibrinolytic function. Circulation. 1993 ; 87: 1969-1973.
43. Paraskevas KI, Hamilton G., Cross JM, Mikhailidis DP Atherosclerotic renal artery stenosis: association with emerging vascular risk factors. Nephron Clin Pract. 2008 ; 108: c56 - c66.
44. Kloner RA, Textor SC, Tavel ME Renovascular hypertension: problems in evaluation and management. Chest. 2002 ; 121 ; 964-968.
45. Bloch MJ, Pickering T. Renal vascular disease: medical management, angioplasty and stenting. Semin Nephrol. 2000 ; 20: 474-488.
46. Isles CG, Robertson S., Hill D. Management of renovascular disease: a review of renal artery stenting in ten studies. Q J Med. 1999 ; 92: 159-167.
47. Webster J., Marshall F., Abdalla M., et al. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. J Hum Hypertens. 1998 ; 12: 329-335.
48. van Jaarsveld BC, Krijnen P., Pieterman H., et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med. 2000 ; 342: 1007-1014.
49. Plouin PF, Chatellier G., Darné B., Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Hypertension. 1998 ; 31: 822-829.
50. Cardiovascular Outcomes in Renal Atherosclerotic Lesions. Web site http://www.clinicaltrials.gov.
51. Gavras H., Brunner HR, Thurston H., Laragh JH Reciprocation of renin dependency with sodium volume dependency in renal hypertension. Science. 1975 ; 188: 1316-1317.
52. Stivali G., Cerroni F., Bianco P., Fiaschetti P., Cianci R. Images in cardiovascular medicine. Carotid plaque reduction after medical treatment. Circulation. 2005 ; 112: e276 - e277.
53. Shepherd J., Kastelein JJ, Bittner V., et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007 ; 2: 1131-1139.
54. Oĝ€™Keefe JH Jr, Cordain L., Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004 ; 43: 2142-2146.
55. de Lorenzo F., Feher M., Martin J., Collot-Teixeira S., Dotsenko O., McGregor JL Statin therapy-evidence beyond lipid lowering contributing to plaque stability. Curr Med Chem. 2006 ; 13: 3385-3393.